Human metapneumovirus (HMPV) and COVID-19 are respiratory viruses with similar transmission via airborne particles, respiratory droplets, contaminated surfaces and direct contact. Both cause initial symptoms such as fever, cough, nasal congestion and, in some cases, shortness of breath. HMPV spreads more slowly than COVID-19 and mainly affects the respiratory tract, while COVID-19 affects a wider range of organs. HMPV has a lower mortality rate, is less fatal, but can be dangerous for infants and people with weakened immune systems. It is seasonally avoided in winter and spring, especially by children, the elderly and the immunocompromised. Unlike the new SARS-CoV-2, HMPV has been around for decades, most people have partial immunity to it, and it has no pandemic potential. Preventive measures include hygiene, hand disinfection and wearing masks. Symptoms of HMPV resemble a cold or flu, in severe cases bronchiolitis or pneumonia.